PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG and Novartis AG hereinafter collectively referred to as “Novartis”) also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a squeeze-out of MorphoSys’ minority shareholders..

PLANEGG/慕尼黑，德国——（商业新闻短讯）——MorphoSys AG（FSE:MOR；NASDAQ:MOR）今天宣布，在诺华于2024年5月成功完成对MorphoSys的收购后，该公司已与诺华BidCo AG和诺华AG签订退市协议。诺华BidCo Germany AG（与诺华BidCo AG和诺华AG合称“诺华”）也告知MorphoSys，他们打算通过挤压MorphoSys的少数股东，将MorphoSys合并为诺华。。

In April 2024, Novartis submitted a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares, offering MorphoSys shareholders € 68.00 per share in cash (the “Takeover Offer”). The acceptance period of the Takeover Offer and the statutory two-week additional acceptance period ended on May 13, 2024, and May 30, 2024, respectively.

2024年4月，诺华提交了所有已发行的MorphoSys无面值无记名股票的自愿公开收购要约，向MorphoSys股东提供每股68.00欧元的现金（“收购要约”）。收购要约的接受期和法定的两周额外接受期分别于2024年5月13日和2024年5月30日结束。

As of June 20, 2024, Novartis holds approximately 91.04% of the total MorphoSys share capital, including purchases by Novartis outside of the Takeover Offer. As a result, Novartis is the majority shareholder of MorphoSys, making MorphoSys a Novartis company..

截至2024年6月20日，诺华持有MorphoSys总股本的约91.04%，包括诺华在收购要约之外的收购。因此，诺华是MorphoSys的大股东，使MorphoSys成为诺华公司。。

MorphoSys and Novartis Sign Delisting Agreement

MorphoSys与诺华签署退市协议

Following the settlement of the Takeover Offer, MorphoSys and Novartis today signed an agreement confirming that Novartis intends to launch a public delisting purchase offer (the “Delisting Offer”) for all outstanding MorphoSys no-par value bearer shares that are not presently held by Novartis. Novartis will offer MorphoSys shareholders € 68.00 per share in cash, corresponding to its preceding Takeover Offer..

收购要约达成和解后，MorphoSys和诺华今天签署了一份协议，确认诺华打算对诺华目前未持有的所有已发行MorphoSys无面值无记名股票发起公开退市收购要约（“退市要约”）。诺华将向MorphoSys股东提供每股68.00欧元的现金，与其之前的收购要约相对应。。

The Delisting Offer document is expected to be published by Novartis in early July 2024 after the German Federal Financial Supervisory Authority (“BaFin”) has approved its publication, in accordance with the provisions of the German Securities Acquisition and Takeover Act. Once the Delisting Offer document is published by Novartis, a four-week (but not less than 20 U.S.

在德国联邦金融监督管理局（“BaFin”）根据《德国证券收购和收购法案》的规定批准其发布后，诺华预计将于2024年7月初发布退市要约文件。一旦诺华发布退市要约文件，为期四周（但不少于20美元）。

business days) offer period for MorphoSys shareholders to tender their shares will commence..

将开始MorphoSys股东投标其股份的报价期。。

Following publication of the Delisting Offer document, the MorphoSys Management Board and Supervisory Board will issue a joint reasoned statement in accordance with sec. 27 of the German Securities Acquisition and Takeover Act. Additionally, in accordance with U.S. securities laws, Novartis will file the Delisting Offer document and a Tender Offer Statement on Schedule TO, and MorphoSys will file the joint reasoned statement and a Solicitation/Recommendation Statement on Schedule 14D-9 with the U.S.

在退市要约文件发布后，MorphoSys管理委员会和监事会将根据《德国证券收购与收购法》第27节的规定发布联合合理声明。此外，根据美国证券法，诺华将按计划向美国提交退市要约文件和要约收购声明，MorphoSys将按计划14D-9向美国提交联合理由声明和招标/推荐声明。

Securities and Exchange Commission (the “SEC”)..

美国证券交易委员会（SEC）。。

Following BaFin approval, the Delisting Offer document and additional information relating to the Delisting Offer will be published by Novartis on this website: https://www.novartis.com/investors/morphosys-acquisition/delisting-purchase-offer. The Tender Offer Statement on Schedule TO and the Solicitation/Recommendation Statement on Schedule 14D-9 will be made available on the SEC’s website at www.sec.gov and under the “SEC Filings” section of the MorphoSys website at www.morphosys.com/en/investors..

在BaFin批准后，诺华将在以下网站上发布退市要约文件和与退市要约相关的其他信息：https://www.novartis.com/investors/morphosys-acquisition/delisting-purchase-offer.将在美国证券交易委员会网站www.SEC.gov和MorphoSys网站www.MorphoSys.com/en/investors的“SEC备案”部分提供附表14D-9的要约收购声明和招标/推荐声明。。

Following the publication of the Delisting Offer document by Novartis, MorphoSys will apply for revocation of the admission to trading of MorphoSys shares on the regulated market of the Frankfurt Stock Exchange. MorphoSys also intends to delist from NASDAQ. After the delisting becomes effective, MorphoSys shares will no longer be traded on the regulated market of the Frankfurt Stock Exchange or on NASDAQ, and follow-up obligations from such a public listing no longer apply.

。MorphoSys还打算从纳斯达克退市。退市生效后，MorphoSys股票将不再在法兰克福证券交易所的受监管市场或纳斯达克交易，并且此类公开上市的后续义务不再适用。

Additionally, following deregistration with the SEC, MorphoSys will no longer be required to file reports with the SEC. Both the delisting from the Frankfurt Stock Exchange and the delisting from NASDAQ are expected to take place in the third quarter of 2024..

此外，在美国证券交易委员会注销登记后，MorphoSys将不再需要向美国证券交易委员会提交报告。法兰克福证券交易所的退市和纳斯达克的退市预计将于2024年第三季度进行。。

MorphoSys and Novartis Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders

Novartis also informed MorphoSys of their intention to merge MorphoSys into Novartis. In this context, Novartis has proposed entering negotiations with the MorphoSys Management Board regarding a merger agreement.

诺华还告知MorphoSys他们打算将MorphoSys合并到诺华。在这种情况下，诺华建议与MorphoSys管理委员会就合并协议进行谈判。

Given Novartis holds approximately 91.04% of the total MorphoSys share capital, Novartis is able to facilitate a squeeze-out of MorphoSys’ minority shareholders in connection with such a merger. Novartis will therefore seek the transfer of MorphoSys’ minority shareholders’ shares to Novartis against an adequate cash compensation (merger squeeze-out).

鉴于诺华持有MorphoSys总股本的约91.04%，诺华能够在合并中挤出MorphoSys的少数股东。。

The amount of the cash compensation has not yet been determined..

现金补偿金额尚未确定。。

It is planned that the necessary shareholders’ resolution on the merger squeeze-out will be adopted at the MorphoSys Annual General Meeting expected to take place in August 2024.

。

About MorphoSys

关于MorphoSys

At MorphoSys, we are driven by our mission: More life for people with cancer. As a global biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts.

在MorphoSys，我们的使命是：为癌症患者提供更多的生命。作为一家全球生物制药公司，我们开发并提供创新药物，渴望重新定义癌症的治疗方式。MorphoSys总部位于德国Planegg，其美国业务位于马萨诸塞州波士顿。

To learn more, visit us at www.morphosys.com and follow us on Twitter at X and LinkedIn..

要了解更多信息，请访问我们的网站www.morphosys.com，并在推特X和LinkedIn上关注我们。。

Additional Information and Where to Find It

其他信息以及在哪里可以找到

The delisting offer described in this communication (the “Delisting Offer”) has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of MorphoSys AG (the “Company”). The final terms and further provisions regarding the Delisting Offer will be in the offer document once the publication of the offer document by Novartis BidCo AG (the “Bidder”) has been approved by the German Federal Financial Supervisory Authority (the “BaFin”), after which the offer document will be filed with the U.S.

本函件中描述的退市要约（“退市要约”）尚未开始。本通信既不是购买MorphoSys AG（“公司”）股份的要约，也不是出售MorphoSys AG（“公司”）股份的要约。一旦诺华投标公司（“投标人”）发布的报价文件得到德国联邦金融监管局（“BaFin”）的批准，有关退市报价的最终条款和进一步规定将在报价文件中，之后报价文件将提交给美国。

Securities and Exchange Commission (the “SEC”). A solicitation and an offer to buy shares of the Company will be made only pursuant the offer document. In connection with the Delisting Offer, the Bidder and Novartis AG will file a Tender Offer Statement on Schedule TO with the SEC (together with the offer document, an Offer to Purchase including the means to tender and other related documents, the “Delisting Offer Documents”), the Company’s management board and supervisory board will issue a joint reasoned statement in accordance with sec.

美国证券交易委员会（“SEC”）。仅根据要约文件进行招标和要约购买公司股份。关于退市要约，投标人和诺华公司将按时向美国证券交易委员会提交一份投标要约声明（连同要约文件、包括投标方式和其他相关文件的收购要约，简称“退市要约文件”），公司管理委员会和监事会将根据美国证券交易委员会的规定发布一份联合合理声明。

27 of the German Securities Acquisition and Takeover Act and the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC (together with the joint reasoned statement, the “Recommendation Statements”). THE COMPANY’S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE DELISTING OFFER DOCUMENTS AND THE RECOMMENDATION STATEMENTS BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE DELISTING OFFER.

根据《德国证券收购与收购法》第27条的规定，公司将按照附表14D-9向美国证券交易委员会提交一份征集/推荐声明（连同联合理由声明，简称“推荐声明”）。敦促公司股东和其他投资者阅读退市要约文件和推荐声明，因为它们将包含重要信息，在就退市要约做出任何决定之前，应仔细阅读这些信息。

The Delisting Offer Documents and the Recommendation Statements will be distributed to all stockholders of the Company in accordance with German and U.S. securities laws. The Tender Offer Stateme.

退市要约文件和推荐声明将根据德国和美国证券法分发给公司所有股东。投标报价说明了我的情况。

In addition to the Offer to Purchase, including the means to tender and certain other Delisting Offer Documents, as well as the Solicitation/Recommendation Statement, the Company files other information with the SEC. The Company’s filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov and are also available free of charge under the “SEC Filings” section of the Company’s website at www.morphosys.com/en/investors..

。。

In order to reconcile certain areas where German law and U.S. law conflict, Novartis AG and the Bidder expect to request no-action and exemptive relief from the SEC to conduct the Delisting Offer in the manner described in the offer document.

为了调和德国法律和美国法律冲突的某些领域，诺华公司和投标人希望不要求美国证券交易委员会采取行动和豁免救济，以要约文件中描述的方式进行退市要约。

Acceptance of the Delisting Offer by stockholders residing outside Germany and the United States of America may be subject to further legal requirements. With respect to the acceptance of the Delisting Offer outside Germany and the United States, no responsibility is assumed for the compliance with such legal requirements applicable in the respective jurisdiction..

居住在德国和美利坚合众国境外的股东接受退市要约可能需要进一步的法律要求。。。

Forward-Looking Statements

前瞻性声明

This communication contains certain forward-looking statements concerning the Company, the Bidder and the Delisting Offer that involve substantial risks and uncertainties. Forward-looking statements include any statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “goal,” “may,” “might,” “plan,” “predict,” “project,” “seek,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” and similar expressions.

该通信包含有关公司、投标人和退市要约的某些前瞻性陈述，涉及重大风险和不确定性。前瞻性陈述包括任何包含“预期”、“相信”、“估计”、“期望”、“打算”、“目标”、“可能”、“可能”、“计划”、“预测”、“项目”、“寻求”、“目标”、“潜在”、“将会”、“将会”、“可能”、“应该”、“继续”等词语的陈述以及类似的表述。

In this communication, the Company’s forward-looking statements include statements about the expected timetable for the consummation of the Delisting Offer and the delisting; the Company’s plans, objectives, expectations and intentions; and the financial condition, results of operations and business of the Company and Novartis AG..

在本通讯中，公司的前瞻性声明包括关于完成退市要约和退市的预期时间表的声明；公司的计划、目标、期望和意图；以及公司和诺华公司的财务状况、经营成果和业务。。

The forward-looking statements contained in this communication represent the judgment of the Company as of the date of this communication and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of the Company, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements.

本通讯中包含的前瞻性陈述代表公司截至本通讯日期的判断，涉及已知和未知的风险和不确定性，可能导致公司的实际业绩、财务状况和流动性、业绩或成就或行业业绩与此类前瞻性陈述中明示或暗示的任何历史或未来业绩、财务状况和流动性、业绩或成就存在重大差异。

In addition, even if the Company's results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: uncertainties as to the timing of the Delisting Offer; uncertainties as to how many of the Company’s stockholders will tender their stock in the Delisting Offer; the possibility that competing offers will be made; the effects of the acquisition of MorphoSys by Novartis AG on relationships with employees, other business partners or governmental entities; that the Bidder and Novartis AG may not realize the potential benefits of the acquisition of MorphoSys by Novartis AG; transaction costs associated with the Delisting Offer; potential operational difficulties with integrating MorphoSys with Novartis AG; that the Company’s expectations may be incorrect; the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements; the Company's reliance on .

此外，即使公司的业绩、业绩、财务状况和流动性以及经营所在行业的发展与此类前瞻性报表一致，也可能无法预测未来时期的业绩或发展。可能导致实际结果与前瞻性声明预期不同的风险和不确定性包括：退市要约时间的不确定性；不确定公司有多少股东将在退市要约中投标其股票；提出竞争报价的可能性；诺华公司收购MorphoSys对员工、其他商业伙伴或政府实体关系的影响；投标人和诺华公司可能无法实现诺华公司收购MorphoSys的潜在利益；与退市要约相关的交易成本；将MorphoSys与诺华公司整合的潜在运营困难；公司的期望可能不正确；；公司的依赖。